Scarica l'app Stockscreener
72.61
0.06%
0.04
Dopo l'orario di chiusura:
72.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bio Techne Corp Borsa (TECH) Ultime notizie
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package - Insider Monkey
Robert V Baumgartner Exercises Options, Realizes $754K - Benzinga
What Does Bio-Techne Corporation's (TECH) Latest Move Mean for Midcap Stocks Investors? - Kalkine Media
Form 4 Bio-Techne Corp For: 25 September - Investing.com India
Form 4 Bio-Techne Corp For: 25 September By Investing.com - Investing.com South Africa
Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes. - Stock Titan
Bio-Techne shareholders approve $11.3 billion merger with German Merck - AKM.RU
What Does Shareholder Approval Mean for Bio-Techne's (NASDAQ:TECH) Merck KGaA Deal? - Kalkine Media
Is Bio-Techne Stock Outperforming the Nasdaq? - barchart.com
Form 8K Bio-Techne Corp For: 23 September By Investing.com - Investing.com Canada
Form 8K Bio-Techne Corp For: 23 September - Investing.com India
Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle - AllSci
Bio-Techne (TECH) Opens Düsseldorf Hub As Fair Value Questions Come Into Focus - simplywall.st
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - Investing News Network
Bio-Techne shareholders approve Merck KGaA acquisition - Investing.com
Bio-Techne Shareholders Approve Takeover by Merck KGaA - marketscreener.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Investing News Network
Bio-Techne Opens New Customer Experience Center in Germany - marketscreener.com
Bio-Techne opens customer experience center in Düsseldorf - Investing.com
Bio-Techne Corp (TECH) Investor Outlook: Navigating Market Dynamics with a Focus on Growth Potential - DirectorsTalk Interviews
Ademi LLP investigates Bio-Techne sale to Merck KGaA - scanx.trade
Bio-Techne Corporation (TECH) Options ChainYahoo Finance - Yahoo! Finance Canada
Bio-Techne issues supplemental merger disclosures amid shareholder lawsuit - Investing.com
Form 8K Bio-Techne Corp For: 14 September By Investing.com - Investing.com Nigeria
Bio-Techne supplements proxy disclosures after shareholder suit, seeks shareholder vote on Sept. 23 - TradingView
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? - Eastern Progress
TECH: Bio-Techne Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN - GlobeNewswire Inc.
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
IVD Raw Material Market Report Now Available — Forecasts Market Growth from $21.5B (2026) to $31.1B by 2031, Profiling Merck KGaA, Thermo Fisher, Bio-Techne, Fapon Biotech, and 21 Other Key Players - Yahoo Finance
Bio-Techne Corp (TECH) Stock Analysis: Navigating Its Current Valuation and Growth Potential - DirectorsTalk Interviews
Bio-Techne Corp (NASDAQ: TECH) Share Price, TECH Stock News, TECH Share Price & Updates - Kalkine
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Bio-Techne Corp (TECH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio-Techne (TECH), What Is Behind The Latest Attention? - simplywall.st
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - Investing News Network
Legal & General buys $19.51M stake in Bio-Techne - app.dealroom.co
Bio-Techne Corp (TECH) Stock Analysis: Evaluating the Balance Between Growth Potential and Current Valuation - DirectorsTalk Interviews
Bio-Techne Corp (TECH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Bio-Techne To Be Acquired by Merck KGaA - Morningstar
Bio-Techne draws fresh institutional cash as revenue climbs to $321M - app.dealroom.co
BIO-TECHNE Corp FY 2026: Revenue $1.22B, EPS $1.16— 10-K Summary - TradingView
Bio-Techne Gives FTC More Time On $11.3B Merck Deal - Law360
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - TradingView
Bio-Techne (TECH) Momentum: Adds 0.06% to Close at $72.32 in the Current Update; Price Context: the Current Price Sits Inside the Supplied Technical Range on the DayHedge Fund Favorites - careplusvn.com
Bio-Techne (Nasdaq: TECH) investors to vote on Merck cash takeover - Stock Titan
Bio-Techne (TECH) Quarterly Results: EPS Does Not Reach the Reported Estimate in Latest Trading; Price Reaction - careplusvn.com
Bio-Techne (NASDAQ: TECH) GC gets new RSU grants, no stock sales - Stock Titan
Bio-Techne (NASDAQ: TECH) grants CFO 22,438 and 36,459 RSUs - Stock Titan
Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29 - Stock Titan
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):